Akari Therapeutics Plc — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Akari Therapeutics raised approximately $8.6M in Q2 2026 ($5.5M private placement + $3.1M warrant exercises; $8.0M net proceeds) from long-term strategic investors. The company is advancing its lead ADC candidate AKTX-101 through IND-enabling activities targeting a Phase 1 clinical trial launch in mid-2027. Akari also established a research collaboration with Whitehawk Therapeutics to explore dual-payload ADC applications combining its PH1 spliceosome-modulating payload with Whitehawk's topoisomerase I payload, and presented preclinical data at ASCO 2026 showing synergistic anti-tumor activity of PH1 combined with an approved KRAS inhibitor in KRAS-mutated pancreatic cancer models.
Why this rating
Financing of $8.6M is ~57% of company market cap; extends runway and de-risks near-term operations. Strategic partnership and ASCO data validation are secondary positives. Pre-clinical stage with execution risk ahead.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.